Galmed Pharma rises after positive results of liver drug formulation study

Eocene

18/11/2025 14:49

** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O rise 7% to $1.13

** Company says its experimental drug, aramchol meglumine, showed positive results in an early-stage study

** GLMD says aramchol meglumine granules are absorbed much better into the body than free acid tablets — about five times better for the 400 mg dose and three times better for the 200 mg dose

** Company is testing its drug for the treatment of liver conditions, gastrointestinal cancers and cardiometabolic diseases

** Up to last close, stock down 67.1% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))